

INNOVA CAPTAB LIMITED  
1281/1, Hilltop Industrial Estate, Near  
EPIP, Phase-I, Jharmajri, Baddi, Dist.  
Solan (H.P.)-173205 India.  
Phone: +91-1795-650820



**February 14, 2024**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**BSE Symbol: INNOVACAP**  
**BSE Scrip Code: 544067**

**National Stock Exchange of India Limited**  
Exchange Plaza, 5th Floor  
Plot No. C/1, "G" Block  
Bandra-Kurla Complex  
Bandra (E), Mumbai – 400 051  
**NSE Symbol: INNOVACAP**

Dear Sir/Madam,

**Subject: Regarding delisting of "Sharon Bio-Medicine Limited" (material subsidiary of the Company)**

Pursuant to Regulation 30 (read with Part A of Schedule III) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), we wish to inform you that the "Sharon Bio- Medicine Limited" (**material subsidiary of Company**) under Resolution Plan approved by the Hon'ble Mumbai Bench of National Company Law Tribunal (NCLT) under Section 31 of the Insolvency and Bankruptcy Code (IBC), 2016 has been accorded approval for delisting of the equity shares w.e.f. February 20, 2024 from:

1. National Stock Exchange of India (NSE) vide Circular Ref. No: 0260/2024 dated February 13, 2024
2. BSE Limited vide Notice No. 20240213-35 dated February 13, 2024

This is for your information and records.

Thanking you,

Yours faithfully,  
For **Innova Captab Limited**

**Neeharika Shukla**  
**Company Secretary & Compliance Officer**  
**Membership No.: A42724**

**Encl:A/a**

1. National Stock Exchange of India (NSE)-Circular Ref. No: 0260/2024 dated February 13, 2024
2. BSE, vide Notice No. 20240213-35 dated February 13, 2024.

## National Stock Exchange of India

### Circular

Department: Listing	
Download Ref No: NSE/CML/ 60668	Date: February 13, 2024
Circular Ref. No: 0260/2024	

To All Members

#### **Sub: Delisting of equity shares of Sharon Bio-Medicine Limited (Symbol - SHARONBIO)**

It is hereby notified that the admission to dealings in securities of Sharon Bio-Medicine Limited shall be withdrawn (delisted) w.e.f. February 20, 2024. The details are as under: -

Sr. No	Name of The Company	Symbol	Reason For Suspension
1.	Sharon Bio-Medicine Limited	SHARONBIO	Delisting of equity shares of Bio-Medicine Limited pursuant to the Resolution plan Approved by the Hon'ble Mumbai Bench of National Company Law Tribunal (NCLT) under Section 31 of the Insolvency and Bankruptcy Code (IBC), 2016

**For and on behalf of  
National Stock Exchange of India Limited**

**Manasi Sawant  
Senior Manager**



No. 20240213- 35

**NOTICE**

**Sub: Delisting of Sharon Bio-Medicine Limited (Scrip Code: 532908).**

Trading Members of the Exchange are hereby informed that pursuant to order by the Hon'ble National Company Law Tribunal, Mumbai Bench, dated May 17, 2023, Sharon Bio-Medicine Limited. ("the Company") applied for delisting of its equity shares.

The Company has confirmed that it has complied with the requirements of NCLT order dated May 17, 2023 for delisting.

Further the above scrip will be delisted from the Exchange records w.e.f. Tuesday, February 20, 2024.

Trading Members of the Exchange are requested to take note of the above.

In case of any clarifications Trading Members may please contact Mr. Prasad Bhide on Tel. No. 022 – 2272 8388

A handwritten signature in black ink, appearing to read 'Rupal Khandelwal', is written over a horizontal dashed line.

**Rupal Khandelwal**  
**Deputy General Manager**  
**Date: February 13, 2024**

LO\Delisting\PB\IP\93\2023-24

February 13, 2024

**Ms. Rakhi Makhloga**  
Company Secretary  
Sharon Bio-Medicine Limited  
W 34 & 34 / 1, MIDC, Taloja, Raigad,  
Maharashtra, 410208

Dear Madam,

**Sub: Delisting of the Equity Shares of Sharon Bio-Medicine Limited (Scrip Code: 532908)**

This is in reference to your application regarding the delisting of the equity shares of **Sharon Bio-Medicine Limited (Scrip Code: 532908)**.

Please find enclosed herewith a copy of the delisting notice (Notice No: 20240213-35 dated February 13, 2024) pertaining to the discontinuation in trading and delisting of the equity shares of the Company.

Yours faithfully,



**Rupal Khandelwal**  
Deputy General Manager



**Prasad Bhide**  
Senior Manager

Encl.: as above